Alzheimer's Prevention Research and

Slides:

Advertisements

Similar presentations

Healthy Purdue Stacey L. Mobley, PhD, RD, CNSD Assistant Professor Department of Foods and Nutrition A Platform for Research in Disease Prevention and.

Advertisements

AD Research Update Steven H. Ferris, PhD Friedman Professor and Director NYU Alzheimer’s Disease Center Silberstein Alzheimer’s Institute Center for Cognitive.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

1 Women & Heart Disease Julia C. Orri, Ph.D. Biol. 330 November 21, 2006.

Vital Signs/Blood pressure. Blood Pressure Arterial blood pressure is a measure of pressure exerted by the blood as flows through the arteries. (measured.

Metabolic Syndrome Jacque De Fouw RN, MSN Health Educator.

Physical Activity and Reduction of Breast Cancer Risk.

Heart Disease Map.

The Early Childhood Roots of Adult Health: Closing the Gap Between What We Know and What We Do JACK P. SHONKOFF, M.D. JULIUS B. RICHMOND FAMRI PROFESSOR.

Lifestyle Medicine 101 Presented by ACLM Professionals in Training Executive Board 2014.

MI: Risk Factors and Primary Prevention. Risk Factors Factors that appear to increase the general population’s chances of experiencing a health problem.

METABOLIC SYNDROME From PubMed Health A service of the National Library of Medicine, National Institutes of Health. A.D.A.M. Medical Encyclopedia, Atlanta,

Decision presented by the committee board members: Nicholas Mann & Katelyn Strasser FUTURE FUNDING FOR ALZHEIMER’S DISEASE October 14, 2014 MPH 543 Leadership.

ALZHEIMER’S PART 2. AD VIDEO

Alzheimer’s Disease Landscape

Progress Report on Alzheimer’s Disease Taking the Next Steps NIA NIH.

Alzheimer's Disease was named after Dr.Alois Alzheimer in 1906.

How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

Grow Your Brain at Any Age Majid Fotuhi, MD PhD Howard County Office on Aging Columbia, MD March 28, 2014.

Six Steps to a Better Brain Majid Fotuhi, MD PhD March 6, 2014.

PTSC Week October 2010© Marilyn Hughes Gaston, M.D. and Gayle K. Porter, Psy.D., Rev All Rights Reserved. Prime Time Sister Circles.

The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.

1 From Cause to Movement Shaping a World Without Alzheimer’s Through Advocacy, Volunteerism, Referral and Science Ian Kremer, Esq. Advocacy & Outreach.

Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.

Progressive, degenerative disorder Attacks the brain's neurons Results in loss of memory, thinking and language skills, and behavioral changes Confusion.

How To Grow Your Hippocampus in Three Months Majid Fotuhi, MD PhD Founder and Chief Medical Officer NeurExpand Brain Center Nothing to disclose.

Do you remember what you ate for dinner two days ago?

Is It Alzheimer’s? The Latest Update on Optimal Evaluation and Treatment of Patients with Memory Loss Majid Fotuhi, MD PhD March 5, 2014.

 2010 Cengage-Wadsworth Preventing Cardiovascular Disease Chapter 11.

Epidemiology of Alzheimer’s Disease

Top Diseases in America Why are most Americans dying? How important is living a long healthy life to you? If it is very important, please pay close attention.

Module 2: Alzheimer’s & Other Dementias – The Basics A Public Health Approach to Alzheimer’s and Other Dementias.

The National Kidney Foundation is the largest organization in the U.S., dedicated to the awareness, prevention, and treatment of kidney disease.

Module 3: Alzheimer’s Disease – What is the Role of Public Health? A Public Health Approach to Alzheimer’s and Other Dementias.

School for hypertensive patients as a new health promotion and disease prevention technology in hospitals and out-patient clinics MD Eganyan R.A., PhD.

Alzheimer’s Disease Today and Tomorrow First case reported in 1906 Reported by Alois Alzheimer Patient Augusta D. first treated at 46 years old Paranoia,

Alzheimer's disease 蕭尚益丁唯洋蔡欣容. Outline introductionDisease mechanismPreventConclusion.

A PUBLIC HEALTH APPROACH TO ALZHEIMER’S AND OTHER DEMENTIAS ALZHEIMER’S & OTHER DEMENTIAS – THE BASICS.

Need For Action. Blood glucose levels are higher than normal but not yet diabetes ** 1 in 3 American adults (79 million) have prediabetes Occurs before.

Diabetes Leilani G. Daligcon. Introduction b b There are two types of diabetes. b b Certain cultures are more prone to it. b b Nutritious eating will.

A PUBLIC HEALTH APPROACH TO ALZHEIMER’S AND OTHER DEMENTIAS ALZHEIMER’S DISEASE – WHAT IS THE ROLE OF PUBLIC HEALTH?

Alzheimer Disease: An Overview. What is Dementia? Dementia is a set of symptoms, which includes loss of memory, understanding, and judgment.

Laura Baker, PhD Internal Medicine, Neurology, & Public Health Sciences Wake Forest School of Medicine Winston-Salem, NC USA.

José L Molinuevo, Craig Ritchie, Miia Kivipelto

Assignment 2: Common health problems in Saudi Arabia (25%)

Opportunities in Dementia

Whitney Wharton, PhD Cognitive Neuroscientist Assistant Professor Department of Neurology Emory University.

Preventing Cardiovascular Disease

The Health Benefits of Physical Activity

What will it take to develop an effective Alzheimer’s drug?

Diabetes Mellitus.

Diabetes Health Status Report

Chapter 10 Diet and Health

Recognizing Your Risk for Cardiovascular Disease

COGNITIVE DECLINE IN THE WORKPLACE

Modifying Disease Course in Alzheimer's Disease

New Therapies in Alzheimer's Disease

Progress Report on Alzheimer’s Disease

Early Dementia Distinguishing AD From MCI

José L Molinuevo, Craig Ritchie, Miia Kivipelto

I Can’t Find My Keys – Should I Be Worried?

מחלת אלצהיימר: עבר, הווה ועתיד

Ongoing Research With Vascular Risk Factors and the RAS in Individuals at Risk for AD Whitney Wharton, PhD Assistant Professor,

in Younger and Older African Americans and Whites

Association between cognitive impairment and cerebrovascular disease

Presentation transcript:

Alzheimer's Prevention Research and Inflammation Whitney Wharton, PhD Associate Professor, SON, SOM Emory University

Overarching Research Goal: To identify modifiable risk factors that may delay or prevent AD Implement pharmaceutical and lifestyle interventions Vascular risk factors and AD biomarkers (NIA K01) RCT with a BP med in African Americans (Alz Assoc PTC) Caregiver Stress (NIA Admin supp. to address health disparities) Inflammation and immune cell profiles (R01) Tango for African American female AD family caregivers (VA, NIA R01) Painting / Photography for AD patients and family caregivers Caregiver intervention (Savvy Caregiver) in LGB AD caregivers Sex hormones (CSF and blood) and CSF AD biomarkers, inflammation, sleep, and brain blood flow and volume (pending R01) RCT with a DRI on AD CSF biomarkers, neuroimaging and the RAS (pending R01)

Early Detection MCI Mild AD Moderate AD Severe AD Increasing Age Normal Cognition MCI Mild AD Worse Cognitive Abilities  better Start Treatment HERE Moderate AD Severe AD 95 Years Increasing Age

Shifting the curve What factors can we identify that…. Are linked to cognitive decline Are linked to the pathological hallmarks of AD (plaques and tangles) Occur during Midlife TREATABLE / REVERSIBLE

Risk Factors and Alzheimer’s disease Alzheimer’s is associated with: Midlife Hypertension Midlife Hypercholesterolemia Inflammation Obesity Diabetes Sleep Disruption Sex Hormones What are the environmental risk factors?

Who is most at risk for AD? African Americans Women Middle Age Increased Vascular risk Family History (genetics +….) Caregivers To Help the Most people Possible, You Must Target Those Most at Risk!!

Race differences in CSF p-tau and t-tau, but not Abeta Race modified the relationship between t-tau & IL-9 (p=0.018), and p-tau and IL-9 (p<0.001)

Sex and Inflammation Postmenopausal women taking HT, but not women opting not to take HT, had significantly different IL-7 levels in plasma and CSF vs. premenopausal women. Direction of change in IL-7 differed according to the biofluid.

A cohort of middle age FH+

Available Data for Collaboration Health Data Medical and medication history Cognition Vascular ultrasound (PWV, FMD, EndoPat) Ambulatory BP Stress, nutrition, exercise, sleep Biomarkers Blood (plasma, buffycoat, serum, whole blood) CSF (AD biomarkers, RAS biomarkers, inflammation) Urine

Thank You